Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Retained Earnings (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Retained Earnings for 13 consecutive years, with -$2.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 16.0% to -$2.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 billion, a 16.0% decrease, with the full-year FY2025 number at -$2.1 billion, down 16.0% from a year prior.
  • Retained Earnings was -$2.1 billion for Q4 2025 at Madrigal Pharmaceuticals, down from -$2.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $468000.0 in Q4 2023 to a low of -$2.1 billion in Q4 2025.
  • A 5-year average of -$971.4 million and a median of -$760.2 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: surged 1562.5% in 2023, then plummeted 4149423.81% in 2024.
  • Madrigal Pharmaceuticals' Retained Earnings stood at -$667.3 million in 2021, then skyrocketed by 100.0% to -$32000.0 in 2022, then soared by 1562.5% to $468000.0 in 2023, then tumbled by 385185.47% to -$1.8 billion in 2024, then fell by 16.0% to -$2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Retained Earnings are -$2.1 billion (Q4 2025), -$2.0 billion (Q3 2025), and -$1.9 billion (Q2 2025).